STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
<p>Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.</p>